APA (7th ed.) Citation

McNerney, K. O., Karageorgos, S., Ferry, G. M., Wolpaw, A. J., Burudpakdee, C., Khurana, P., . . . Bassiri, H. (2022). TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy. OncoImmunology, 11(1), 1. https://doi.org/10.1080/2162402X.2022.2075204

Chicago Style (17th ed.) Citation

McNerney, K. O., et al. "TH-MYCN Tumors, but Not Tumor-derived Cell Lines, Are Adrenergic Lineage, GD2+, and Responsive to Anti-GD2 Antibody Therapy." OncoImmunology 11, no. 1 (2022): 1. https://doi.org/10.1080/2162402X.2022.2075204.

MLA (9th ed.) Citation

McNerney, K. O., et al. "TH-MYCN Tumors, but Not Tumor-derived Cell Lines, Are Adrenergic Lineage, GD2+, and Responsive to Anti-GD2 Antibody Therapy." OncoImmunology, vol. 11, no. 1, 2022, p. 1, https://doi.org/10.1080/2162402X.2022.2075204.